It's interesting about the 2 mg dosage. I suspect that better results from the lower dosage (rather than higher) may not carry over to the onc. trial-that's really just a guess, though. As I recall, higher doses were more efficacious in skin indications. I don't think they thoroughly understand dosage w/this drug yet. But rather than being a neg., I think it offers hope for improved results.
News 
Market Data 
Discover 
